# Recombinant Human Thrombopoietin (rhTPO) in Management of Immune Thrombocytopenia (ITP) in Pregnancy

> **NCT02270801** · PHASE3 · UNKNOWN · sponsor: **Shandong University** · enrollment: 30 (estimated)

## Conditions studied

- Immune Thrombocytopenia
- Pregnancy

## Interventions

- **DRUG:** rhTPO

## Key facts

- **NCT ID:** NCT02270801
- **Lead sponsor:** Shandong University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-10
- **Primary completion:** 2017-01
- **Final completion:** 2017-04
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2016-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02270801

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02270801, "Recombinant Human Thrombopoietin (rhTPO) in Management of Immune Thrombocytopenia (ITP) in Pregnancy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02270801. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*